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Figure 1. Frequency of peak galactomannan serum ratios in 22 hematology patients with proven
and probable invasive aspergillosis. A case patient is a patient with invasive aspergillosis primarily
treated with caspofungin who experiences a subsequent unexpected increase in galactomannan
level ( ).Pp .03
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Reply to Miceli and Anaissie
To the Editor—We thank Miceli et al.
[1] for their response to our article in
which they suggest that our observation
of an unexpected increase of circulating
galactomannan (GM) was due to failure
of the infection to respond to caspofungin
therapy rather than a paradoxical effect
[2]. Our laboratory has 110 years of ex-
perience with GM detection in patients
with hematological malignancy, and we
have not previously observed such high
levels of circulating antigen (figure 1). Un-
like our patient, the patients described by
Maertens et al. [3] received antifungal
treatment prior to caspofungin therapy.
One study presented by Miceli et al. [1]
as evidence of the nonexistence of a par-
adoxical effect relates to combination an-
tifungal therapy with another echinocan-
din (micafungin and ravuconazole) in an
animal model for invasive aspergillosis
(IA) and differs from our patient, who
received primary monotherapy with cas-
pofungin [4]. Two other studies men-
tioned also fail to exclude a paradoxical
effect and cannot be compared with our
case. First, the kinetics of GM in patients
who experience chronic granulomatous
disease are known to be different from
those in hematological patients [5]. Sec-
ond, the results by van Vianen et al. [6]
have not been consistently found by other
researchers. Wiederhold et al. [7] detected
an increase in quantitative lung tissue As-
pergillus DNA (by RT-PCR) in neutro-
penic mice with pulmonary aspergillosis
after treatment with caspofungin, 4 mg/kg
per day, compared with 1 mg/kg per day.
Our clinical observation is supported by
both an animal model [8] that was not
referred to by Miceli et al. [1] and our
own in vitro experiment, in which fungal
biomass was correlated with the release of
GM by the causative Aspergillus strain fol-
lowing exposure to caspofungin [2].
The lack of a consistent description of
a paradoxical effect should not provide the
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impetus to definitely conclude that an
increase and subsequent decrease of GM
after administration of caspofungin rep-
resents treatment failure. In our patient,
this was not the case. An increase and de-
crease in GM during therapy does not nec-
essarily presage the outcome in one way
or another. Our point was that one should
exercise caution in interpreting the GM
serum ratio in patients who receive cas-
pofungin—or any other antifungal, for
that matter.
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Illness in Travelers Visiting
Friends and Relatives: What
Can Be Concluded?
To the Editor—We were interested to
read the GeoSentinel report by Leder et
al. [1] that focused on an important group
of international travelers who, to date,
have not been clearly defined in terms of
demographic characteristics and travel-
related morbidity. We suggest that there
are significant issues related to the design,
analysis, interpretation, and conclusions
of the study that require comment. Al-
though Leder and colleagues acknowledge
several limitations in their report, practi-
tioners who are not familiar with the na-
ture of the GeoSentinel program and/or
who do not work with migrant travelers
may not fully appreciate the significance
of these limitations.
First, although the classification of trav-
elers into 3 groups looks appealing, the
classifications have been applied retroac-
tively to the data, and the consequences
of this are significant. The retrospective
cohort nature of the study design limits
the interpretation of outcomes to a cohort
association and diminishes the generaliz-
ability of the conclusions to wider practice
outside of the participating GeoSentinel
centers.
Second, there is no design evidence that
the recategorization of travelers into “im-
migrant visiting friends and relatives,”
“traveler visiting friends and relatives,”
and “tourist,” as defined within the report,
is either robust or reliably discriminating
for travel-related risk or for health out-
comes.
Third, the data recruitment allows for
the introduction of both patient referral
and selection bias. This may create epi-
demiological associations that may not be
representative of travelers outside of the
study group. GeoSentinel sites are often
academic or tertiary care centers, and are
predominantly based in America; thus,
they may be biased towards recruiting
tourists rather than travelers visiting
friends and relatives. Patterns of access to
medical service by migrants may differ
from those of the host population [2]. Al-
lowable health insurance coverage and is-
sues of willingness to pay for services in
the visited nation [3] may influence pre-
travel and posttravel service use by trav-
elers visiting friends and relatives. Insur-
ance coverage may be linked to the study’s
observations of early clinical presentation
by tourist travelers, compared with the
travelers visiting friends and relatives (who
have limited insurance) .
Other design considerations include the
acquisition of diseases, such as malaria,
which are primarily related to the desti-
nation rather than the reason for travel.
Analysis of travel to regions of West Africa
and East and southern Africa would have
been more reflective of actual risk than
reasons for travel. There is evidence that
travelers visiting friends and relatives are
overrepresented as travelers [4] to both
Asia and sub-Saharan Africa, and the rel-
ative high proportion of disease prevalence
in the group may be a reflection of greater
exposure to and not increased likelihood
of disease. The differing pattern of mor-
bidity among the groups of travelers and
immigrants visiting friends and relatives
may relate to their economic status, access
to and use of services, and medical care–
seeking behavior, rather than to travel-
associated risk.
All of these factors combined are design
issues that we believe makes studies like
the Leder et al. [1] study difficult to extend
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